Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
BACKGROUND Olanzapine has demonstrated efficacy in the treatment of acute mania in 2 double-blind , placebo-controlled trials . We describe the results of the open-label extension from one of these trials . METHOD In a 3-week , double-blind study of patients with DSM-IV bipolar I disorder , olanzapine was superior to placebo for the treatment of acute manic symptoms . Of the 139 patients who entered the double-blind phase of the 3-week study , 113 patients continued into the 49-week open-label extension .  Efficacy measurements including the Young Mania Rating Scale ( YMRS ) , the 21-item Hamilton Rating Scale for Depression ( HAM-D-21 ) , the Clinical Global Impressions scale-Bipolar Version , and the Positive and Negative Syndrome Scale and safety measurements including the Simpson-Angus scale , the Barnes Akathisia Scale , and the Abnormal Involuntary Movement Scale were completed throughout . The analysis considered all treatment results , starting with the first olanzapine dose . Adjunctive lithium and fluoxetine were allowed during the open-label extension . RESULTS The mean length of olanzapine treatment was 6.6 months , with a mean modal dose of 13.9 mg/day . A significant mean improvement in the YMRS total score , baseline to endpoint ( -18.01 , p < .001 ) , was observed . During treatment , 88.3 % of patients experienced a remission of manic symptoms ( YMRS total score < or = 12 ) , and only 25.5 % subsequently relapsed ( YMRS total score > or = 15 ) . Significant improvement in HAM-D-21 scores was observed ( p < .001 ) . Forty-one percent of patients were maintained on olanzapine monotherapy . The most common treatment-emergent adverse events reported were somnolence ( 46.0 % ) , depression ( 38.9 % ) , and weight gain ( 36.3 % ) . CONCLUSION During up to 1 year of olanzapine therapy , either as monotherapy or in combination with lithium and /or fluoxetine , patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile . Further double-blind , controlled studies are needed to confirm these results
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .